---
figid: PMC4493053__nihms628780f7
figlink: /pmc/articles/PMC4493053/figure/F7/
number: F7
caption: Genes that were found in the genomic analyses of SHH-MBs to harbor activating
  mutations (green stars), inactivating mutations (red stars), or were found to be
  amplified (MYCN and GLI) are indicated. All these mutations lead to activation of
  GLI proteins and their downstream pathways. Options for targeted treatment are indicated.
  Patients harboring mutations in either PTCH1 or SMO should be responsive to SMO
  inhibitors, whereas patients harboring mutations more downstream in the SHH pathway
  (SUFU, MYCN, and GLI) or in the PI3K/AKT/mTOR and/or PKA-pathways may be treated
  using arsenic trioxide (ATO) or other more specific GLI-inhibitors or PI3K/AKT/mTOR
  inhibitors.
pmcid: PMC4493053
papertitle: Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response
  to Smoothened Inhibition.
reftext: Marcel Kool, et al. Cancer Cell. ;25(3):393-405.
pmc_ranked_result_index: '151094'
pathway_score: 0.9723434
filename: nihms628780f7.jpg
figtitle: Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response
  to Smoothened Inhibition
year: ''
organisms:
- Mus musculus
- Homo sapiens
ndex: 6f07b156-dec5-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4493053__nihms628780f7.html
  '@type': Dataset
  description: Genes that were found in the genomic analyses of SHH-MBs to harbor
    activating mutations (green stars), inactivating mutations (red stars), or were
    found to be amplified (MYCN and GLI) are indicated. All these mutations lead to
    activation of GLI proteins and their downstream pathways. Options for targeted
    treatment are indicated. Patients harboring mutations in either PTCH1 or SMO should
    be responsive to SMO inhibitors, whereas patients harboring mutations more downstream
    in the SHH pathway (SUFU, MYCN, and GLI) or in the PI3K/AKT/mTOR and/or PKA-pathways
    may be treated using arsenic trioxide (ATO) or other more specific GLI-inhibitors
    or PI3K/AKT/mTOR inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MFAP1
  - PIK3CA
  - AKT2
  - PRKACG
  - PIK3CB
  - PIK3R4
  - SHH
  - PRKAR2A
  - AKT3
  - PIK3CG
  - PIK3R3
  - PIK3R6
  - CHKA
  - GLI1
  - PTEN
  - PRKACB
  - PIK3R5
  - PIK3CD
  - AKT1
  - MYCN
  - PRKAR1A
  - PRKAR2B
  - PRKACA
  - SUFU
  - PTCH1
  - MTOR
  - SMO
  - PRKAR1B
  - GSK3B
  - Cancer
genes:
- word: AMP
  symbol: AMP
  source: hgnc_alias_symbol
  hgnc_symbol: MFAP1
  entrez: '4236'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: SHH
  symbol: SHH
  source: hgnc_symbol
  hgnc_symbol: SHH
  entrez: '6469'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: CKI
  symbol: CKI
  source: hgnc_alias_symbol
  hgnc_symbol: CHKA
  entrez: '1119'
- word: GLI
  symbol: GLI
  source: hgnc_prev_symbol
  hgnc_symbol: GLI1
  entrez: '2735'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MYCN
  symbol: MYCN
  source: hgnc_symbol
  hgnc_symbol: MYCN
  entrez: '4613'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: SUFU
  symbol: SUFU
  source: hgnc_symbol
  hgnc_symbol: SUFU
  entrez: '51684'
- word: PTCH1
  symbol: PTCH1
  source: hgnc_symbol
  hgnc_symbol: PTCH1
  entrez: '5727'
- word: mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: SMO
  symbol: SMO
  source: hgnc_symbol
  hgnc_symbol: SMO
  entrez: '6608'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC4493053__F7
redirect_from: /figures/PMC4493053__F7
figtype: Figure
---
